dual anti-CD33/anti-CLL1 CAR T-cell therapy (Sichuan Kelun-Biotech Biopharmaceutical)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Namedual anti-CD33/anti-CLL1 CAR T-cell therapy (Sichuan Kelun-Biotech Biopharmaceutical)
Drug Alias Namedual CD33-CLL1 CAR T-cell therapy (Sichuan Kelun-Biotech Biopharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulators
TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A